Showing 1251 - 1260 of 2237 results

Showing Results for: “Glycemic Index and Diabetes”

Helping Spanish speakers link type 2 diabetes and heart disease and stroke

The American Heart Association and the American Diabetes Association expand landmark Know Diabetes by Heart™ collaboration with Spanish campaign American Heart Association and American Diabetes Association aims to increase awareness and action among Spanish language-dominant people with type 2 diabetes to underscore the link between type 2 diabetes and heart disease and stroke. The announcement comes during Hispanic Heritage Month (September 15 – October 15). The Spanish-language campaign, found at DiabetesdeCorazon.org , is an extension of the American Heart Association and the American

American Diabetes Association® Announces Step Out DC Honorary Chair

The American Diabetes Association® (ADA) is pleased to announce Emmy Award winning journalist, Michelle Marsh of ABC7 as the honorary chair for this year's Virtual Step Out DC. The event is taking place on Saturday, September 26, 2020. The ADA encourages everyone to walk 3.4 miles in support of the 34 million Americans living with diabetes. It is more important than ever to raise awareness around the diabetes epidemic that is ravishing our communities. We will celebrate and honor those thriving with diabetes while helping to propel the mission of the ADA. “I’m thrilled to be serving as the

Insulin Co-Pays Capped at $30 for those in the Granite State with Diabetes

The American Diabetes Association® applauds New Hampshire’s governor and legislature for passing a cap on insulin co-pays Today, New Hampshire House Bill 1280 was signed into law by Governor Chris Sununu. A provision in the law limits cost sharing for insulin to $30 per 30-day supply for those with state-regulated commercial health insurance, a measure supported by the American Diabetes Association (ADA). The new law will take effect on September 14, 2020. Stephen Habbe, Director for State Government Affairs for the ADA, issued the following statement: “One of the most urgent issues faced by

Latest TEDDY Report Outlines Research on Type 1 Diabetes and Celiac Disease

NIDDK study continues to look at possible factors that lead to the development of the diseases in children New results and information surrounding potential “triggers” of the autoimmune process leading to type 1 diabetes (T1D) and how they interact with genetic factors in children at-risk for developing the disease were highlighted in the “Update from the TEDDY Study” symposium today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions. Similar evidence for celiac disease is also being accumulated through the large international study program. The data The

The American Diabetes Association's Statement on Amazon Pharmacy Automatic Coupons for Insulin

“Access to affordable diabetes medications and technology can help people living with diabetes stay healthy and avoid complications. Sadly, some of the 37.3 million Americans living with diabetes can’t afford the treatments they need to survive,” said Charles “Chuck” Henderson, chief executive officer of the American Diabetes Association ® (ADA). “The ADA has been the leading voice in advocating for affordable insulin and diabetes technology. We applaud Amazon Pharmacy for innovating on behalf of people with diabetes and taking important action to help ensure they easily access the treatments

The American Diabetes Association Statement on Novo Nordisk’s Insulin Price Reduction

“The American Diabetes Association ® (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. The ADA has led the charge to enact cost-sharing limits on insulin in 22 states and D.C., and now the first-ever federal copay cap in Medicare. We are pleased that more manufacturers are continuing to take steps to make insulin more affordable, and we hope others follow suit. ADA will keep working to make sure drug rebates are not inflating costs for patients at the pharmacy counter, and we will continue

The American Diabetes Association Statement on the Passing of Congressman Donald Payne Jr.

The American Diabetes Association’s Chief Executive Officer Charles D. “Chuck” Henderson issued the following statement on the passing of Congressman Donald Payne Jr. “This week, the diabetes community lost a true champion as we learned of the passing of Congressman Donald Payne Jr. Congressman Payne Jr. embodied the highest standards of public service and was a champion for people living in his district and in New Jersey. He was a leader amongst his peers and frequently spoke about his own health challenges with diabetes and related conditions, as he fought to ensure that others achieved

The American Diabetes Association Highlights Health Equity in 2023 Impact Report

As Minority Health Month draws to a close, the American Diabetes Association® (ADA) highlighted progress towards health equity in its 2023 Health Equity Impact Report . There are 136 million Americans are living with diabetes or prediabetes and those living in under-resourced communities are more likely to develop diabetes and experience its associated complications. The ADA is striving to build awareness around the disproportionate burden people face when it comes to diabetes care and is working in communities across the country to increase equitable access. “Guided by the ADA’s Healthy

Study Shows Promising Results for Inhaled Insulin as Treatment for Type 1 Diabetes

Findings Reveal Efficacy of Novel Inhaler to Improve Glycemic Control for Patients with Type 1 Diabetes Today, findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes (T1D), were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management. The results were presented as a symposium at the 84th Scientific Sessions of the American Diabetes Association® (ADA) in Orlando, FL. Type 1 diabetes affects 11.6% of the American population and millions of individuals globally , requiring ongoing insulin therapy